{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019525","form_type":"8-K","ticker":null,"cik":"0001642375","company_name":"Guardion Health Sciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.389443+00:00","generated_at":"2026-06-01T23:14:41.545085+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Guardion Q1 net loss $4.7M; ISS backs Activ sale for $17.2M and dissolution plan","bullets":["Q1 revenue $2.999M (-5.8% YoY); net loss $4.747M vs net income $0.533M prior year.","ISS recommends stockholders vote FOR sale of Activ (Viactiv brand) and plan of liquidation.","Activ sale for $17.2M cash; special meeting May 23, 2024; close targeted by June 30, 2024.","Board unanimously recommends approval; expects liquidating distributions above recent stock price.","Cash and equivalents $5.605M as of March 31, 2024; operating cash use improved to $754.6K."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019525","json":"https://secwatch.observer/filing/0001493152-24-019525.json","markdown":"https://secwatch.observer/filing/0001493152-24-019525.md","text":"https://secwatch.observer/filing/0001493152-24-019525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642375/000149315224019525/0001493152-24-019525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642375/000149315224019525/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:14:41.545085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da25f602c21fb28f382032153b33d139eb5f27b4","claim":"Guardion Health Sciences, Inc. reported the three months ended March 31, 2024 results: revenue $2,999,645, net income $(4,746,744).","evidence_excerpt":"the Special Meeting of its Stockholders to vote on these transactions. Financial highlights for the three months ended March 31, 2024 include the following: ● Total revenue was $2,999,645 for the three months ended March 31, 2024, as compared to $3,185,689 for the three months ended March 31, 2023, a decrease of $186,044 or 5.8%. Sales of the Viactiv ® product","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642375/000149315224019525/0001493152-24-019525-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$2,999,645"},{"label":"Net income","value":"$(4,746,744)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}